DODeena A. Oren

Deena A. Oren

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Deena A. Oren has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    OpenTn5: Open-Source Resource for Robust and Scalable Tn5 Transposase Purification and Characterization

    by Jan Soroczynski, Lauren J. Anderson, Joanna L. Yeung, Justin M. Rendleman, Deena A. Oren, Hide A. Konishi, Viviana I. Risca

    Tagmentation combines DNA fragmentation and sequencing adapter addition by leveraging the transposition activity of the bacterial cut-and-paste Tn5 transposase, to enable efficient sequencing library preparation. Here we present an open-source protocol for the generation of multi-purpose hyperactive Tn5 transposase, including its benchmarking in CUT&Tag, bulk and single-cell ATAC-seq. The OpenTn5 protocol yields multi-milligram quantities of pG-Tn5 E54K, L372P protein per liter of E. coli culture, sufficient for thousands of tagmentation reactions and the enzyme retains activity in storage for more than a year.


  • Open Access

    Mechanism of glycoform specificity and in vivo protection by an anti-afucosylated IgG nanobody

    by Aaron Gupta, Kevin S. Kao, Rachel Yamin, Deena A. Oren, Yehuda Goldgur, Jonathan Du, Pete Lollar, Eric J. Sundberg, Jeffrey V. Ravetch

    Immunoglobulin G (IgG) antibodies contain a complex N-glycan embedded in the hydrophobic pocket between its heavy chain protomers. This glycan contributes to the structural organization of the Fc domain and determines its specificity for Fcγ receptors, thereby dictating distinct cellular responses. The variable construction of this glycan structure leads to highly-related, but non-equivalent glycoproteins known as glycoforms. We previously reported synthetic nanobodies that distinguish IgG glycoforms. Here, we present the structure of one such nanobody, X0, in complex with the Fc fragment of afucosylated IgG1. Upon binding, the elongated CDR3 loop of X0 undergoes a conformational shift to access the buried N-glycan and acts as a ‘glycan sensor’, forming hydrogen bonds with the afucosylated IgG N-glycan that would otherwise be sterically hindered by the presence of a core fucose residue. Based on this structure, we designed X0 fusion constructs that disrupt pathogenic afucosylated IgG1-FcγRIIIa interactions and rescue mice in a model of dengue virus infection.


  • Open Access

    Itch receptor MRGPRX4 interacts with the receptor activity–modifying proteins

    by Ilana B. Kotliar, Emilie Ceraudo, Kevin Kemelmakher-Liben, Deena A. Oren, Emily Lorenzen, Tea Dodig-Crnković, Mizuho Horioka-Duplix, Thomas Huber, Jochen M. Schwenk, Thomas P. Sakmar


  • Open Access

    Mechanism of glycoform specificity and protection against antibody dependent enhancement by an anti-afucosylated IgG nanobody

    by Aaron Gupta, Kevin Kao, Rachel Yamin, Deena A. Oren, Yehuda Goldgur, Jonathan Du, Pete Lollar, Eric J. Sundberg, Jeffrey V. Ravetch

    Immunoglobulin G (IgG) antibodies contain a single, complex N -glycan on each IgG heavy chain protomer embedded in the hydrophobic pocket between its Cγ2 domains. The presence of this glycan contributes to the structural organization of the Fc domain and determines its specificity for Fcγ receptors, thereby determining distinct cellular responses. On the Fc, the variable construction of this glycan structure leads to a family of highly-related, but non-equivalent glycoproteins known as glycoforms. We previously reported the development of synthetic nanobodies that distinguish IgG glycoforms without cross-reactivity to off-target glycoproteins or free glycans. Here, we present the X-ray crystal structure of one such nanobody, X0, in complex with its specific binding partner, the Fc fragment of afucosylated IgG1. Two X0 nanobodies bind a single afucosylated Fc homodimer at the upper Cγ2 domain, making both protein-protein and protein-carbohydrate contacts and overlapping the binding site for Fcγ receptors. Upon binding, the elongated CDR3 loop of X0 undergoes a conformational shift to access the buried N -glycan and acts as a ‘glycan sensor’, forming hydrogen bonds with the afucosylated IgG N -glycan that would otherwise be sterically hindered by the presence of a core fucose residue. Based on this structure, we designed X0 fusion constructs that disrupt pathogenic afucosylated IgG1-FcγRIIIa interactions and rescue mice in a model of dengue virus infection.

  • Open Access

    Itch receptor MRGPRX4 interacts with the receptor activity-modifying proteins (RAMPs)

    by Ilana B. Kotliar, Emilie Ceraudo, Kevin Kemelmakher-Liben, Deena A. Oren, Emily Lorenzen, Tea Dodig-Crnković, Mizuho Horioka-Duplix, Thomas Huber, Jochen M. Schwenk, Thomas P. Sakmar

    Cholestatic itch is a severe and debilitating symptom in liver diseases with limited treatment options. The class A G protein-coupled receptor (GPCR) Mas-related GPCR subtype X4 (MRGPRX4) has been identified as a receptor for bile acids, which are potential cholestatic pruritogens. An increasing number of GPCRs have been shown to interact with receptor activity-modifying proteins (RAMPs), which can modulate different aspects of GPCR biology. Using a combination of multiplexed immunoassay and proximity ligation assay we show that MRGPRX4 interacts with RAMPs. The interaction of MRGPRX4 with RAMP2, but not RAMP1 or 3, causes attenuation of basal and agonist-dependent signaling, which correlates with a decrease of MRGPRX4 cell surface expression as measured using a quantitative NanoBRET pulse-chase assay. Finally, we use AlphaFold Multimer to predict the structure of the MRGPRX4-RAMP2 complex. The discovery that RAMP2 regulates MRGPRX4 may have direct implications for future drug development for cholestatic itch.


  • Top Cited Papers
    Open Access

    Enhanced SARS-CoV-2 neutralization by dimeric IgA

    by Zijun Wang, Julio C. C. Lorenzi, Frauke Muecksch, Shlomo Finkin, Charlotte Viant, Christian Gaebler, Melissa Cipolla, Hans-Heinrich Hoffmann, Thiago Y. Oliveira, Deena A. Oren, et al.

    Human dimeric IgA antibodies are potent neutralizers of SARS-CoV-2.


  • Open Access

    Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro

    by Zijun Wang, Julio C. C. Lorenzi, Frauke Muecksch, Shlomo Finkin, Charlotte Viant, Christian Gaebler, Melissa Cipolla, Hans-Heinrich Hoffman, Thiago Y. Oliveira, Deena A. Oren, et al.

    SARS-CoV-2 primarily infects cells at mucosal surfaces. Serum neutralizing antibody responses are variable and generally low in individuals that suffer mild forms of the illness. Although potent IgG antibodies can neutralize the virus, less is known about secretory antibodies such as IgA that might impact the initial viral spread and transmissibility from the mucosa. Here we characterize the IgA response to SARS-CoV-2 in a cohort of 149 individuals. IgA responses in plasma generally correlate with IgG responses and clones of IgM, IgG and IgA producing B cells that are derived from common progenitors are evident. Plasma IgA monomers are 2-fold less potent than IgG equivalents. However, IgA dimers, the primary form in the nasopharynx, are on average 15 times more potent than IgA monomers. Thus, secretory IgA responses may be particularly valuable for protection against SARS-CoV-2 and for vaccine efficacy.